Sandoz Is Covering ‘Six Of Eight’ GLP-1 Opportunities, With Plans To Evolve
Greater Free Cash Flow In Years Ahead Will Fuel Ambitions; API Supply Crucial
“I’ve never launched a drug quite like this,” Sandoz’s CEO Richard Saynor has admitted frankly, as the firm spoke about its plans to launch GLP-1 assets in the future, starting with semaglutide in markets including Canada and Brazil as early as 2026.
